Nonchemical integration of Au/Ag-based reduced graphene nanohybrid combined with 5-Fluorouracil drug to treat cancer cells.

The perpetual lack of advanced strategies to prevent aggressive breast cancer with multiple categories represents challenging scientific society problems. Reduced graphene oxide- can treat disease, which was recently investigated due to its ability to induce apoptosis-based death. This research tested the chemotherapeutics in vitro efficacy of reduced graphene oxide embedded with gold and silver nanoparticles toward drug-sensitive breast cancer cells (MCF-7) and their cytotoxicity. Synthesis of the Au-Ag/rGO-5FU nanocomposites has been conducted using a wet chemical approach with chitosan aid as a pore directing and capping agent. The particle structure and morphology well characterized using different systems. HR-TEM shows a narrow-sized distribution of less than 100 nm, which is proper for cell membranes and medical use. The physical combination of the nanocomposite and 5-FU drug has been conducted mechanically using wet chemistry. The Au/Ag/rGO-5FU material's high activity enables it to produce reactive oxygen radicals, which display a potential against MCF-7 cell lines. All the results, including those obtained via cytometry, use the combination of Au/Ag/rGO-5FU to show a more substantial anticancer influence and more drug stability than pure 5-FU.